I think you have raised a valid point, and it would be interesting to read Stoll's response. EPIX's outcome flies in the face of what Stoll wrote, and might lead him to reconsider his position. If he doesn't want to answer he won't but if he does, we might learn something.
Implicit in Stoll's response is the downside risk: if the trial is too short, cor could be stuck with a false negative. Still, I think it is worth raising the issue with him, particularly if the PET trials are positive.
News 
Market Data 
Discover 
